AMPH:NGS-Amphastar Pharmaceuticals Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | Nasdaq Global Select

Last Closing

USD 41.11

Change

+0.28 (+0.69)%

Market Cap

USD 0.91B

Volume

0.26M

Analyst Target

USD 22.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.64 (+0.46%)

USD 13.68B
VTRS Viatris Inc

-0.59 (-5.00%)

USD 13.36B
ITCI Intracellular Th

-1.44 (-2.15%)

USD 7.72B
LNTH Lantheus Holdings Inc

+1.39 (+1.87%)

USD 4.49B
ALKS Alkermes Plc

+0.16 (+0.66%)

USD 4.11B
ALVO Alvotech

+0.06 (+0.44%)

USD 3.79B
HCM HUTCHMED DRC

+1.35 (+6.93%)

USD 3.23B
AVDL Avadel Pharmaceuticals PLC

-0.42 (-2.58%)

USD 2.99B
INDV Indivior PLC Ordinary Shares

+0.09 (+0.51%)

USD 2.93B
EVO Evotec SE ADR

+0.08 (+1.54%)

USD 2.51B

ETFs Containing AMPH

JSML Janus Henderson Small Cap.. 0.00 % 0.50 %

+0.63 (+1.07%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.53% 28% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.53% 28% F 16% F
Trailing 12 Months  
Capital Gain 14.93% 70% C- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.93% 70% C- 70% C-
Trailing 5 Years  
Capital Gain 90.41% 88% B+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 90.41% 88% B+ 83% B
Average Annual (5 Year Horizon)  
Capital Gain 32.05% 81% B- 86% B+
Dividend Return 32.05% 81% B- 86% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.71% 70% C- 49% F
Risk Adjusted Return 87.29% 99% N/A 95% A
Market Capitalization 0.91B 88% B+ 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 44.70 51% 54%
Price/Book Ratio 2.98 37% 34%
Price / Cash Flow Ratio 10.92 18% 25%
Price/Free Cash Flow Ratio 9.46 22% 28%
Management Effectiveness  
Return on Equity 23.55% 89% 91%
Return on Invested Capital 18.30% 89% 87%
Return on Assets 11.07% 93% 96%
Debt to Equity Ratio 92.21% 23% 26%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.